MPR1d
Pegvaliase Reduces Blood Phenylalanine Levels in Adolescents With PKU
Detailed study results will be presented at an upcoming medical meeting and submitted to health authorities later this year to expand Palynziq’s label to include adolescents.
Clinical Trials Arena3d
BioMarin’s trial for phenylketonuria therapy meets primary efficacy endpoint
BioMarin has reported that the multi-centre Phase III PEGASUS trial of Palynziq (pegvaliase-pqpz) has met its primary ...
BioMarin Seeks Label Expansion For Palynziq After Positive Phase 3 Results In Adolescent Patients
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released topline data from the Phase 3 PEGASUS trial evaluating Palynziq ...
What is a ‘complete’ protein? Add these foods to your diet to build muscle and more
Complete proteins, which include meat and dairy products, make that a little easier because you'll get all nine essential ...
BioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Phase 3 PEGASUS trial evaluating PALYNZIQ® (pegvaliase-pqpz) met its primary efficacy endpoint, demonstrating a statistically ...